ITPP

ITPP, myo-inositol trispyrophosphate, is a synthetic small molecule that acts as an allosteric effector of hemoglobin. It was developed by the groups of Jean-Marie Lehn and Claude Nicolau as a membrane-permeant compound able to enter red blood cells and shift the oxygen-binding behavior of hemoglobin so that oxygen is released more readily to the tissues ^[1]. Chemically it is a pyrophosphate derivative of myo-inositol, related in concept to the natural red-cell effector 2,3-bisphosphoglycerate but capable of crossing the erythrocyte membrane from the outside.

The core action of ITPP is to raise the p50 of hemoglobin, the partial pressure of oxygen at which hemoglobin is half-saturated; a higher p50 means hemoglobin gives up oxygen more easily. In normal mice, ITPP produced a dose-related increase in p50 of up to 31 percent and correspondingly increased maximal exercise capacity, an effect that persisted in transgenic mice with severe heart failure ^[1]. Because so many diseases involve tissue hypoxia, ITPP has been investigated across a wide range of models: it restored right ventricular oxygen tension in a rat model of pulmonary hypertension ^[2], reduced hypoxia and normalized tumor blood vessels to promote antitumor immune responses in cancer models ^[3], and served as an oxygenating agent that lowered hypoxia-inducible factor levels and prevented liver failure after extended liver resection ^[4].

ITPP is not an approved medicine, and its striking performance effects in animals have made it a flagged substance in sport; validated methods exist to detect it in equine urine and plasma because of concerns about its covert use as a doping agent in racehorses ^[5]. It remains an investigational compound studied primarily in the context of hypoxia-related disease and is handled as a research chemical.

ITPP is an experimental allosteric effector of hemoglobin studied only in animals and cell systems; there is no established human safety data, no approved use, and no defined dosing. Altering the oxygen affinity of hemoglobin could plausibly disturb tissue oxygen delivery and cardiovascular physiology in unpredictable ways, and the purity and content of research-grade material are not guaranteed. It is prohibited in sport by anti-doping authorities.

ITPP (myo-inositol trispyrophosphate) was developed in the mid-2000s by chemists including the Nobel laureate Jean-Marie Lehn and Claude Nicolau as a membrane-permeant allosteric effector of hemoglobin, designed to mimic the oxygen-releasing action of natural effectors such as 2,3-bisphosphoglycerate. Early animal work demonstrated that it lowers hemoglobin's oxygen affinity and substantially increases exercise capacity in both healthy mice and mice with severe heart failure. Because relieving tissue hypoxia has broad implications, it was subsequently investigated in pulmonary hypertension and oncology, and a Phase Ib dose-escalation trial in patients with hepatopancreatobiliary tumors was completed and reported in 2021. It continues to be studied as a hypoxia-modifying agent.

ITPP is regarded as an elegant idea in physiology; rather than adding red cells or increasing blood flow, it coaxes the blood already in circulation to give up more of its oxygen. Its animal endurance data are notable, and its ability to normalize tumor blood vessels and improve responses to immunotherapy has drawn oncology interest. A completed Phase Ib clinical trial found it broadly tolerable, with hypercalcemia as the main and manageable side effect. Fairly noted, most efficacy evidence remains preclinical, human data are early, and it is banned in sport as a blood-oxygenation doping agent.